Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2021 Jan 2;127(1):15. doi: 10.1007/s00339-020-04167-0

Marine biomimetics: bromotyrosines loaded chitinous skeleton as source of antibacterial agents

Liubov Muzychka 1, Alona Voronkina 2, Valentine Kovalchuk 3, Oleg B Smolii 1, Marcin Wysokowski 4,5,, Iaroslav Petrenko 5, Diaa T A Youssef 6,7, Irina Ehrlich 8, Hermann Ehrlich 5,9,
PMCID: PMC7776313  PMID: 33424135

Abstract

The marine sponges of the order Verongiida (Demospongiae: Porifera) have survived on our planet for more than 500 million years due to the presence of a unique strategy of chemical protection by biosynthesis of more than 300 derivatives of biologically active bromotyrosines as secondary metabolites. These compounds are synthesized within spherulocytes, highly specialized cells located within chitinous skeletal fibers of these sponges from where they can be extruded in the sea water and form protective space against pathogenic viruses, bacteria and other predators. This chitin is an example of unique biomaterial as source of substances with antibiotic properties. Traditionally, the attention of researchers was exclusively drawn to lipophilic bromotyrosines, the extraction methods of which were based on the use of organic solvents only. Alternatively, we have used in this work a biomimetic water-based approach, because in natural conditions, sponges actively extrude bromotyrosines that are miscible with the watery environment. This allowed us to isolate 3,5-dibromoquinolacetic acid from an aqueous extract of the dried demosponge Aplysina aerophoba and compare its antimicrobial activity with the same compound obtained by the chemical synthesis. Both synthetic and natural compounds have shown antimicrobial properties against clinical strains of Staphylococcus aureus, Enterococcus faecalis and Propionibacterium acnes.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00339-020-04167-0.

Keywords: Chitin, Biomimetics, Bromotyrosines, Antibacterial, Sponges, Secondary metabolites, Spherulocytes

Introduction

In the last decade, marine demosponges belonging to the Verongiida order (Demospongiae: Porifera) [1] have come worldwide to the focus of researchers for a number of reasons. It has been reliably established [2] that the first representatives of this order lived in the waters of the world ocean in the province of Alberta on the territory of present-day Canada 505 million years ago. Modern representatives of the order retained the presence of the basic morphological principles of the structural organization of their skeleton, including their unique chitinous nature [315]. Due to the biomineralization of their branched chitinous skeletons, which can grow up to 1.5 m long [16, 17] these sessile sponges were able to effectively use their stiff and porous constructs for extracting feed by filtering water. However, as a result of water filtration, a huge number of pathogenic viruses, bacteria and fungi enter the inner space of sponge body and must be neutralized. Now, it is well recognized that verongiid sponges developed sophisticated and highly dynamic chemical defense system [18] due to biosynthesis over than 300 diverse brominated compounds (mostly bromotyrosines), which exhibit a rich variety of chemical structures [1928] and have been classified into six main categories, including simple bromotyrosine derivatives, oximes, bastadins, spirocyclohexadienylisoxazolines, spirooxepinisoxazolines and other structural classes (see for overview [20]). Functionally, they are recognized as multitarget drugs [29, 30], with prominent antiviral, antibacterial, antifungal, cytotoxic as well as antifouling activities (see for overview [3142]). Some of poriferan bromotyrosines showed antimetastatic activity [43, 44] as well as have been reported as effective inhibitors of acetylcholinesterase (AChE), that is a clinical marker of Alzheimer’s disease [45].

The indisputable advantages of the Verongiida sponges in comparison with other demosponges include their unique ability to regenerate tissues [46, 47], which determines the progress in their cultivation using marine farming methods [4851]. These marine sponges are now considered as renewable sources of both biological materials (i.e. chitin) and biologically active bromotyrosines, which suggests the possibility of organizing large-scale waste-free production in their natural habitats (Mediterranean, Caribbean, Indonesia, Australia, Guam and Florida). Perspectives of verongiids bioeconomy with respect to bromotyrosines and chitin have been recently analyzed in detail [39].

After early reports of isolation and characterization of such bromotyrosines as 3,5-dibromoverongiaquinol and the dimethyl ketal from two verongiid sponges Verongia fistularis and V. cauliformis in 1967 [52, 53] and 1970 [54], numerous experimental and review reports concerning extraction, identification, biosynthesis, synthesis and modifications as well as practical applications of bromotyrosines of verongiids’ origin have been published (see for overview [20, 5564]). If the multitarget functionality of the biological action of bromotyrosines and their high pharmacological potential are no longer in doubt, the strategies for their extraction from biological raw materials or the development of key ways of efficient and inexpensive synthesis of corresponding analogous substances remain a controversial point. In connection with the latest developments in methods for cultivating verongiid sponges and extracting bromotyrosines with almost 90% yield, this direction is promising, although it may be limited by the specifics of environmental legislation in different countries [39]. An alternative way through the development of appropriate reactions for the synthesis of analogs takes place and is widely presented in the literature (see as examples [6567]). However, in this case, synthesis can be an expensive and multistep procedure. Organic solvents (i.e. methanol, chloroform, less often ethanol) are mainly used in most of the reported works for extraction of bromotyrosines from verongiid sponges, because of their hydrophobic nature. However, biologists are well aware that there are bromotyrosines that easily and very quickly diffuse into and miscible with seawater after mechanical damage of the sponge tissue due to predatory mollusk or fish [6870]. Moreover, it is well known that bromotyrosines in representatives of Aplysinidae family within Verongiida order are synthesized within spherulocytes  [68, 71], highly specialized cells found within skeletal highly brominated [72, 73] chitinous fibers [37] (Fig. 1). These cells seem to be very sensitive to changes in their environment. They are capable of rapid self-destruction and the release of selected bromotyrosines (i.e. aerothionin and homoaerothionin) into sponge mesophyll as well as surrounding seawater [69, 70].

Fig. 1.

Fig. 1

Light microscopy image (a) of the bromotyrosine-producing reddish-coloured spherulocytes localized within chitinous skeletal fibres of Ianthella flabelliformis verongiid demosponge. They can degenerate and apparently release bromotyrosines-rich contents into the intercellular matrix and further into surrounding seawater. These cells remain to be well visible also using scanning electron microscopy (b)

We believe that spherulocytes remain to be responsible for the explosive release of bromotyrosines and, correspondingly for antimicrobial properties of aqueous extracts isolated from the verongiid sponge Aplysina aerophobaas have been reported in 1997 for the first time [74]. We anticipate that insertion of spherulocytes–rich skeletons of this sponge will lead to exudation of large amounts of bromotyrosines determined by osmotic shock. Due to the promising nature of this group of sponges in terms of their cultivation under marine farming conditionsand the prospects for practical application [39], we considered it expedient to determine the presence of water-soluble bromotyrosines in them. Such bromotyrosines acted as an inspiration for the in vitro syntheses of corresponding analogs. Consequently, an additional goal of this study was an attempt to synthesize an analogue of water-soluble bromotyrosines in laboratory conditions and to conduct comparative antimicrobial tests on selected pathogenic and clinical bacterial strains.

In this study, a water extraction approach of the sponge A. aerophoba was achieved. Fractionation of the aqueous extract and purification of the antimicrobial fractions of the extracts gave three bromotyrosin derivatives, including 3,5-dibromoquinolacetic acid (2) along with the previously reportedaeroplysinin-2 (1) and aeroplysinin-1 (3). In addition, compound 2 was prepared synthetically and the antimicrobial activities of the compounds was evaluated. Interestingly, the natural and synthetic 3,5-dibromoquinolacetic acid (2) displayed significant activity especially against pathogene Propionibacterium acnes.

Materials and methods

Sample collection

The demosponge Aplysina aerophoba (Nardo) was collected in the Adriatic Sea (Kotor Bay, Montenegro, 42° 26′ 10.2″ N 18° 45′ 51.7″ E) from the marine aquaculture facility from the depths of 3–5 m by SCUBA diving in 2019. Sponge samples were collected in ziplock bags underwater, brought to the laboratory on ice and washed with water to remove salts. Selected specimens were air-dried in shade for 7 days prior to further treatment.

General experimental procedures

1H and 13C NMR spectra were acquired on Varian Unity Plus 400 (Varian Inc, CA, USA) and Bruker Avance DRX 500 (Bruker, Switzerland) spectrometers using DMSO-d6 as a solvent and tetramethylsilane as an internal standard. Mass spectra were recorded on an LC–MS instrument with chemical ionization (CI). LC–MS data were recorded on an Agilent 1100 HPLC equipped with a diode-matrix and mass-selective detector Agilent LC/MSD SL. Column: Zorbax SB-C18, 4.6 mm × 15 mm. Eluent: A, acetonitrile–H2O with 0.1% of trifluoroacetic acid (TFA; 95:5); B, H2O with 0.1% of TFA. Flow rate: 1.8 mL/min. Thin layer chromatography (TLC) was detected on Polygram SIL G/UV254 plate (Machery-Nagel, Germany) using CHCl3–MeOH (19:1) as eluent. Column chromatography was performed using silica gel 60 (230–400 mesh, Merck, Germany) as the stationary phase. Melting points were determined using a Boetius melting point apparatus (Boetius Franz Kustner, Germany).

Isolation and purification of compounds 1–3

The dried A. aerophoba sponge (220.0 g) was treated with deionized H2O (1 L) for 8 days at room temperature. The combined intensive reddish colored aqueous extracts (pH 5.3) were concentrated under vacuum, dissolved in MeOH and the MeOH soluble fraction (17 g) was partitioned on a silica gel column (80 × 5 cm) eluted with CHCl3-MeOH gradients (from 100:0 to 0:100) to afford 57 fractions. Fractions 31–38 were combined and the residue (110 mg) was dissolved in CH2Cl2-hexane (2:1), where aeroplysinin-2 (1) (13 mg) was obtained by crystallization as white crystals. The remaining filtrate was left for another 3-5 days, where 3,5-dibromoquinolacetic acid (2) (26 mg) was obtained with CH2Cl2 as a white solid. Similarly, fractions 44-46 were combined, and the residue (34 mg) was dissolved in CHCl3, where aeroplysinin-1 (3) (18 mg) was obtained by crystallization. The structures of compounds 1-3 are shown in Fig. 2.

Fig. 2.

Fig. 2

Chemical structures of compounds 1–3

Spectral data of compounds 1–3 (see Supplementary Data)

Aeroplysinin-2 (1) [75, 76]

White crystals. Mp = 109–111 °C. 1H NMR (400 MHz, DMSO-d6): δH 6.56 (s, 1H, H-5 or OH), 6.51 (s, 1H, OH or H-5), 5.14 (s, 1H, H-1), 3.70 (s, 3H, H3-9), 2.99 (1H, d, J = 16.8 Hz, H-7a), 2.88 (1H, d, J = 16.8 Hz, H-7b); 13C NMR (125 MHz, DMSO-d6): δC 172.9 (qC, C-8), 149.6 (qC, C-3), 135.5 (CH, C-5), 117.1 (qC, C-4), 105.9 (qC, C-2), 87.3 (CH, C-1), 75.4 (qC, C-6), 60.4 (CH3, C-9), 41.6 (CH2, C-7); MS (CI): m/z = 339.4 [M − H]+.

3,5-Dibromoquinolacetic acid [(3,5-dibromo-1-hydroxy-4-oxocyclohexa-2,5-dien-1-yl)acetic acid] (2)

White solid. Mp = 192–194 °C (decomp.). 1H NMR (400 MHz, DMSO-d6): δH 12.48 (br s, 1H, COOH), 7.65 (s, 2H, H-2 and H-6), 6.41 (br s, 1H, OH), 2.79 (s, 2H, H2-7); 13C NMR (125 MHz, DMSO-d6): δC 172.8 (qC, C-4), 170.3 (qC, C-8), 153.3 (2 × CH, C-2 and C-6), 119.9 (2 × qC, C-3 and C-5), 71.7 (qC, C-1), 43.8 (CH2, C-7); MS (CI): m/z = 324.7 [M − H]+.

Aeroplysinin-1 (3) [39, 75]

White crystals. Mp = 119–120 °C. 1H NMR (400 MHz, DMSO-d6): δH 6.30 (s, 1H, H-5), 6.19 (d, J = 8.0 Hz, 1H, OH), 6.13 (s, 1H, OH), 3.92 (d, J = 8.0 Hz, 1H, H-1), 3.62 (s, 3H, H3-9), 2.77 (s, 2H, H2-7); 13C NMR (125 MHz, DMSO-d6): δC 147.1 (qC, C-3), 133.7 (CH, C-5), 119.4 (qC, C-2), 118.6 (qC, C-8), 113.7 (qC, C-4), 77.5 (CH, C-1), 73.6 (qC, C-6), 59.8 (CH3, C-9), 26.4 (CH2, C-7); MS (CI): m/z = 339.8 [M + H]+.

Synthesis of 3,5-dibromoquinolacetic acid (2)

The synthesis of 3,5-dibromoquinolacetic acid (2) started bromination of a commercial sample of (4-hydroxyphenyl)acetic acid (4) under the previously reported conditions [54] to afford (3,5-dibromo-4-hydroxyphenyl)acetic acid (5), which was converted to the dienone-derivative (2) by further oxidation using a mixture of nitric and acetic acids (1:20). 3,5-Dibromoquinolacetic acid (2) was not obtained in a high yield as a result of a parallel replacement reaction occurred, in addition to the oxidation, in which one bromine atom in 5 was replaced by a nitro group into give (3-bromo-4-hydroxy-5-nitrophenyl)acetic acid (6). Despite that, the synthesized 3,5-dibromoquinolacetic acid (2) was obtained as an individual white solid without the need of column chromatography in contrast to the previously described methods [54, 77] (Scheme 1).

Scheme 1.

Scheme 1

Synthesis of 3,5-dibromoquinolacetic acid (2). Reagents and conditions: a Br2, AcOH, rt, 72 h; b HNO3, AcOH, 10 °C, 15 h

Synthesis of (3,5-dibromo-4-hydroxyphenyl)acetic acid (5)

Compound 5 was synthesized by bromination of (4-hydroxyphenyl)acetic acid (4) according to the method described in [54].

Spectral data of (3,5-dibromo-4-hydroxyphenyl)acetic acid (5)

Colorless needle-shaped crystals. Mp = 197–198 °C. 1H NMR (400 MHz, DMSO-d6): δH 12.40 (br s, 1H, OH), 9.82 (br s, 1H, OH), 7.44 (s, 2H, Ar), 3.52 (s, 2H, CH2); 13C NMR (125 MHz, DMSO-d6): δC 172.7 (qC, C=O), 149.7 (qC), 133.7 (2 x CH), 130.1 (qC), 111.9 (2 × qC), 38.8 (CH2); MS (CI): m/z = 310.9 [M + H]+.

Synthesis of 3,5-dibromoquinolacetic acid (2) and (3-bromo-4-hydroxy-5-nitrophenyl)acetic acid (6)

(3,5-Dibromo-4-hydroxyphenyl)acetic acid (5) (500 mg)was added to a solution of a mixture 70% nitric acid (0.25 mL) and acetic acid (5 mL) at 10 °C, and the reaction mixture was stirred at 10 °C for 3 h. Water (100 mL) was added to the reaction mixture after leaving overnight at 10 °C, following by filtration of the resulting precipitate (compound 6, 160 mg). The remaining filtrate was extracted with EtOAc (3 × 20 mL) and the combined organic layers were dried over Na2SO4. The solvent was removed under reduced pressure. The oily residue was dissolved in CH2Cl2 (10 mL) resulting in a white precipitate. After filtration of the supernatant, compound was obtained as a solid, which was crystallized from EtOAc/CH2Cl2 (3:1) to give an analytical sample of 2 (90 mg).

Spectral data of the synthetic 3,5-dibromoquinolacetic acid (2)

White solid. Mp = 193–194 °C (decomp.). 1H NMR (400 MHz, DMSO-d6): δH 12.44 (br s, 1H, OH), 7.64 (s, 2H, Ar), 6.39 (br s, 1H, OH), 2.79 (s, 2H, CH2); 13C NMR (125 MHz, DMSO-d6): δC 172.9 (qC, C=O), 170.4 (qC, C=O), 153.5 (2 x CH), 119.9 (2 × qC), 71.8 (qC), 43.9 (CH2); MS (CI): m/z = 324.9 [M − H]+.

Spectral data of (3-bromo-4-hydroxy-5-nitrophenyl)acetic acid (6)

Yellow needle-shaped crystals. Mp = 198–199 °C. 1H NMR (400 MHz, DMSO-d6): δH 12.52 (br s, 1H, OH), 10.96 (br s, 1H, OH), 7.91 (s, 1H, Ar), 7.89 (s, 1H, Ar), 3.65 (s, 2H, CH2); 13C NMR (125 MHz, DMSO-d6): δC 172.6 (qC, C=O), 148.6 (qC), 140.7 (CH), 137.3 (qC), 128.2 (qC), 125.7 (CH), 113.7 (qC), 38.7 (CH2); MS (CI): m/z = 375.9 [M − H]+.

Antimicrobial evaluation of the compounds

For the determination of antimicrobial activity, S. aureus (ATCC 6538-P) and clinical multiresistant strains of P. acnes 41 (isolated from selected papules of patients with acne), E. faecalis VNMU068 (NCBI Biosample ID SAMN13701844) and K. pneumoniae VNMU131 (NCBI Biosample ID SAMN13701847) (isolated from selected infected wounds) were used. The clinical strains were isolated and cultured in Department of Microbiology of the National Pirogov Memorial Medical University, Vinnytsya, Ukraine. A separate stock solution of each compound under evaluation were prepared using 10 mg of each compound in 1 mL of DMSO: H2O (1:5) solution.

Qualitative antimicrobial evaluation of the compounds

For qualitative antimicrobial evaluations of the compounds, S. aureus, P. acnes and K. pneumoniae were used. The antimicrobial evaluation was carried out using a well-diffusion susceptibility test [7880] using meat peptone agar (MPA). The inocula of the strains were spread into sterile agar plate surfaces. Then, 5-mm diameter holes were made aseptically. In each hole, 20 µL (0.2 mg of substance) of the stock solution of the compounds were added. All agar plates were incubated for 24 h at 37 °C.

Evaluation of the MIC and MBC of 3,5-dibromoquinolacetic acid (2)

For the quantitative antimicrobial determination of 3,5-dibromoquinolacetic acid (2), S. aureus, P. acnes and E. faecalis were used. The MIC and MBC were evaluated using a broth dilution method [81]. To 0.5 mL of liquid nutritive environment, 0.5 mL of a water–DMSO (9:1) mixture containing 5 mg of compound 2 was added, followed by double serial dilutions. 0.1 mL of inoculum with 106 colony-forming units (CFU) of bacteria was added with calibrated bacteriological loop to all solutions, than they were incubated for 24 h at 37 °C.

In all experiments, sterility control of nutritive environment, control of microorganism growth without compound, as well as control of diluents for antimicrobial activity and a positive control of cultures with a commercially available antibiotics (i.e. with erythromycin for qualitative antimicrobial evaluations of the compounds using well-diffusion method for S. aureus, P. acnes and K. pneumonia; with erythromycin and benzoyl peroxide for S. aureus and P. acnes MIC and MBC evaluation (broth dilution method) and with vancomycin for E. faecalis (due to resistance of the strain to Erythromycin and Benzoyl peroxide) were used.

Results

Purification of compounds 1–3 from the aqueous extract of A. aerophoba

The resulted aqueous extract of the cultivated A. aerophoba sponge was evaporated under reduced pressure, and the residue was dissolved in MeOH. The MeOH-soluble residue was concentrated and partitioned on a silica gel column using a CHCl3-MeOH gradients (from 100–0 to 0–100%) to purify aeroplysinin-2 (1), 3,5-dibromoquinolacetic acid [(3,5-dibromo-1-hydroxy-4-oxocyclohexa-2,5-dien-1-yl)acetic acid] (2) and aeroplysinin-1 (3) (Fig. 2). In this report, the isolated compounds (1-3) were identified by comparing their spectroscopic data (1H, 13C NMR and MS data) with the previously reported data in the literature. 3,5-Dibromoquinolacetic acid (2) is reported here for the first time from a natural source. It was previously synthesized by Sharma and co-workers [54]. The compounds were also identified by comparing its spectral data with the reported values [54]. Furthermore, compound 2 was synthesized and its NMR and MS spectroscopic data were found to be identical with the natural compound.

The purity of all isolated and synthesized compounds was proved using spectroscopic data (1H, 13C NMR and MS data). All substances are individual (100% purity), which is confirmed by the presented spectra (for details see Supplementary Data). In addition, to achieve 100% purity, some compounds were further purified by crystallization.

3,5-Dibromoquinolacetic acid was obtained from the aqueous extract of an air-dried sample of the sponge A. aerophoba (2A) and that obtained by direct synthesis (2B), as well as aeroplysinin-2 (1) and (3,5-dibromo-4-hydroxyphenyl)acetic acid (5) (see Table 1 and Fig. 3), which seem to be the precursors for the 3,5-dibromoquinolacetic acid. Compounds 1, 2A, 2B, 5 were evaluated for their antimicrobial activities against Staphylococcus aureus, P. acnes and Klebsiella pneumoniae (Table 1). In addition, the remaining supernatant (Fraction C), obtained after isolation of compound 2, was subjected for antimicrobial screen against the same pathogens (Table 1).

Table 1.

Results of the qualitative antimicrobial evaluation of the compounds

Sample ID S. aureus P. acnes K. pneumoniae
Compound 1 + +
Compound 2A (synthetic) + +
Compound 2B (natural) + +
Fraction C + + +
Compound 5

+ Observed growth inhibition, − no observed growth inhibition

Fig. 3.

Fig. 3

Growth inhibition by samples represented in Table 1 against S. aureus (ac); P. acnes (d) and K. pneumoniae (e) (scale bar 1 cm)

Structural determination of compounds 1–3

The compounds were determined by interpretation of their 1H and 13C and MS spectroscopic data. All data are in good agreement with the previously reported values in the literature. Therefore compounds 1-3 were assigned as aeroplysinin-2 (1) [75, 76], 3,5-dibromoquinolacetic acid(2) [54], and aeroplysinin-1 (3) [39, 75], respectively (See Supporting data for more details). It is worth to mention that this is the first report about isolation of compound 2 from a natural source. It was previously reported as a synthetic compound [54].

Results of the antimicrobial activities of the compounds

The results of the quantitative antimicrobial evaluation of the synthetic and natural 3,5-dibromoquinolacetic acid against P. acnes were reported here for the first time. The MIC and MBC values against the clinical strain of P.acnes under thestudy were determined at 7.8 and 31.2 µg/mL, respectively (Table 2). For the synthetic (2A) and natural (2B) 3,5-dibromoquinolacetic acid, the minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) against S. aureus, P. acnes and Enterococcus faecalis were evaluated separately (Table 2).

Table 2.

Results of quantitative antimicrobial evaluation of natural and synthetic 2

Compound (mg/mL)
S. aureus P. acnes E. faecalis
MIC MBC MIC MBC MIC MBC
2A (synthetic) 125 125 7.8 31.2 31.2 31.2
2B (natural) 125 125 7.8 31.2 31.2 31.2

Discussion

In contrast to previously reported organic reagents based methods (i.e. EtOH, MeOH and CH2Cl2) for extraction of bromotyrosines from A. aerophoba [39, 7679], we used a new biomimetic approach here including water extraction at room temperature for the first time to avoid destruction/change of thermolabile ingredients including artifacts. The compounds 1-3 have been previously reported to be present in A. aerophoba and other representatives of the order Verongiida [39, 7577, 8288], but this is the first report where these compounds were obtained from a room temperature aqueous extract of the sponge.

3,5-Dibromoquinolacetic acid (2) (Fig. 2) was first obtained by [54] as a component of the mixture resulted by acidic hydrolysis of the new brominated derivative obtained from the MeOH extract of the marine sponge Verongia fistularis. These authors also described first the direct synthesis of the 3,5-dibromoquinolacetic acid [54], which included stages of bromination and oxidation as well as the final phase of chromatographic purification. The structure of the 3, 5-dibromoquinolacetic acid was confirmed by spectral data.

Later, Minale et al. [76] obtained another secondary metabolite named aeroplysinin-2 (1) (Fig. 2) from the sponge A. aerophoba and defined its stereochemical structure. When aeroplysinin-2 was left, it was converted into 3,5-dibromoquinolacetic acid via a probable photochemical reaction [76]. Despite the species was later revised by researchers to A. cavernicola [20, 89], aeroplysinin-2 was confirmed to be present in A. aerophoba [82, 84].

With regards to the reports about the role of the light as a stimulating factor on the growth of colonies of selected marine verongid sponges [90] and the effect of the depth on the colonies on the variation bromotyrosins’ compositions [68], the probability of effect of photochemical reactions in the bioconversion of bromotyrosines [91] is poorly investigated. In natural environment, bioconversion of complex brominated isoxazoline derivatives into simple molecules occurs in 40 s [92] that represent a “vivid example for dynamic bioconversions of natural products that generate highly efficient chemical weapons precisely when and where needed” [34].The rates of aerothionin exudate into artificial seawater were measured as 7.7 × 10−4 μg min−1 g−1 dry weight of the verongiid sponge A. fistularis for native, undamaged and in well-lit shallow water habituating organism [68]. However, after a simulated injury, the sponge responds by exuding 10–100 times of the regular amounts under regular conditions. To the best of our knowledge, extraction of bromotyrosines from verongiid sponges using artificial seawater under laboratory conditions is still unknown. Therefore, we suggest that corresponding experiments with deionized as well as seawater extracts obtained from the sponge A. aerophoba under UV-light exposure in dependence of intensity, time and temperature as well as oxidation rate should be carried out soon.

Unfortunately, there is still lack on data concerning the antimicrobial activities of natural 3,5-dibromoquinolacetic acid in contrast to the synthetic compound. There is a report about the moderate activity of 3,5-dibromoquinolacetic acid against gram-positive bacteria, without any effect against gram-negative bacteria [77]. (3,5-Dibromo-4-hydroxyphenyl) acetic acid (5), which was obtained through a bromination step of synthesis, did not show any microbial growth inhibition as well.

However, a mixture of the substances obtained from fraction’s filtrate after isolation of 3,5-dibromoquinolacetic acid has displayed antimicrobial activities against both Gram-positive and Gram-negative bacteria. Similarly, aeroplysinin-2 also showed some antimicrobial activities, which in agreement with the previous reports [88]. A broad antimicrobial spectrum for aeroplysinin-1 in micromolar range was also reported [20, 39, 75, 88]. These results may represent the potential of using future preparation of aqueous extracts containing a mixture of bromotyrosins’. Similarly, commercially available preparations containing a mixture of components in extracts with broad-spectrum antimicrobial activity due to synergistic effect of the components.

The MIC of the synthetic 3,5-dibromoquinolacetic acid (2) was previously defined at 6.25 µg/mL against S. aureus, while it was > 100 µg/mL against other strains [77]. In contrast to previously reported data, while defining MIC and MBC for the synthetic and natural 3,5-dibromoquinolacetic acid, the MIC and MBC values were equal for both compounds at 125 µg/mL for S. aureus and 31.2 for E. faecalis.

P. acnes (recently renamed as Cutibacterium acnes) [93] is the cause of inflammation and pustule formationin in 650 million people (reported in 2010) to have had chronic skin infection known as acne disease worldwide [93]. Interestingly, the alternative marine drug, named sargafuran, isolated from the brown algae Sargassum macrocarpum previously showed an MIC value of 15 μg/mL against P. acnes [94]. This value is twofold of the MIC value of 3,5-dibromoquinolacetic acid against P. acnes. Therefore, our results presented here represent the potential of using 3,5-dibromoquinolacetic acid as a scaffold that can be developed into novel and more effective drugs against C. acnes. Unfortunately, exact mechanisms of antibacterial activity of bromotyrosines remain poorly investigated. It was suggested that they can inhibit the DNA synthesis and, probably, DNA gyrase [20]. Recently, due to COVID problematic, studies on antiviral activity of poriferan secondary metabolites are in trend. The ability of marine demosponges to collect viruses in their bodies due to their water filtering activity is well recognized [95, 96]. How sponges neutralize viruses is still unknown. Intriguingly, selected bromotyrosines (i.e. aeroplysinin-1, 19-deoxyfistularin 3, purealidin B, fistularin 3 and 3-bromo-5-hydroxy-O-methyltyrosine) effectively inhibited HIV replication [97]. Corresponding experiments with isofistularin-3, aeroplysisin and 3,5-dibromoquinolacetic acid against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are in progress now in our Lab.

We also suggest that occurrence of poriferan chitin that is loaded with bromotyrosines in native state will stimulate the development of highly sensitive analytical methods for identification [98].

Conclusions

In conclusion, we anticipate, with confidence that the evolutionary success of Verongiida sponges to survive in the oceans over than 500 million years of existence may be due to their unique ability of to protect themselves through their chitinous skeleton, production of chemical warfare like the bromotyrosines, which could be lipophilic or hydrophilic. Previously, the attention of researchers was exclusively drawn to lipophilic bromotyrosines, the extraction methods of which were logically based on the use of appropriate organic solvents. Without a doubt, this was not a biomimetic approach, because in natural conditions, sponges actively extrude bromotyrosines that are miscible with the watery environment. We suggest that, the existence of such water-soluble bromotyrosine derivatives, including 3,5-dibromoquinolacetic acid in an aqueous extract of the dried demosponge A. aerophoba, after a storage of the sponge at room temperature in the light, is an example of a chemical conversion of more complex bromotyrosines, that is originally exist in the sponge into smaller molecules. Such phenomenon reported in this study can be used as the basis for the development of new, effective and easy-to-solve key way for the extraction of certain bromotyrosines from aqueous extracts of their sponges.

Supplementary Information

Below is the link to the electronic supplementary material.

Acknowledgments

This work was partially supported by DFG Project HE 394/3, SMWK Project no. 02010311 (Germany), by Alexander von Humboldt Polish Honorary Research Scholarship (FNP, Poland) and by the Ministry of Science and Higher Education (Poland) through a financial subsidy to PUT, No. 0912/SBAD/2006.

Funding

This work was partially supported by DFG Project HE 394/3, SMWK Project no. 02010311 (Germany), by Alexander von Humboldt Polish Honorary Research Scholarship (FNP, Poland), OPUS19 (NCN Poland) and by the Ministry of Science and Higher Education (Poland) through a financial subsidy to PUT.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article contains no animal studies by any of the authors re-quiring endorsement from the ethical committee. In fact, according to the current regulatory studies, no ethical authorization is required for invertebrates like A. aerophoba.

Consent to participate

All of the co-workers have agreed to participate.

Consent for publication

All of the co-workers have agreed to publication.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Marcin Wysokowski, Email: marcin.wysokowski@put.poznan.pl.

Hermann Ehrlich, Email: hermann.ehrlich@esm.tu-freiberg.de.

References

  • 1.Bergquist PR, de Cook SC. Syst Porifera. Berlin: Springer; 2002. p. 1081. [Google Scholar]
  • 2.Ehrlich H, Rigby JK, Botting JP, Tsurkan MV, Werner C, Schwille P, Petrášek Z, Pisera A, Simon P, Sivkov VN, Vyalikh DV, Molodtsov SL, Kurek D, Kammer M, Hunoldt S, Born R, Stawski D, Steinhof A, Bazhenov VV, Geisler T. Sci. Rep. 2013;3:1–6. doi: 10.1038/srep03497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ehrlich H, Krautter M, Hanke T, Paul S, Knieb C, Heinemann S, Worch H. J. Exp. Zool. 2007;308B:473. doi: 10.1002/jez.b.21174. [DOI] [PubMed] [Google Scholar]
  • 4.Ehrlich H, Simon P, Carrillo-Cabrera W, Bazhenov VV, Botting JP, Ilan M, Ereskovsky AV, Muricy G, Worch H, Mensch A, Born R, Springer A, Kummer K, Vyalikh DV, Molodtsov SL, Kurek D, Kammer M, Paasch S, Brunner E. Chem. Mater. 2010;22:1462. doi: 10.1021/cm9026607. [DOI] [Google Scholar]
  • 5.Ehrlich H, Steck E, Ilan M, Maldonado M, Muricy G, Bavestrello G, Kljajic Z, Carballo JL, Schiaparelli S, Ereskovsky A, Schupp P, Born R, Worch H, Bazhenov VV, Kurek D, Varlamov V, Vyalikh D, Kummer K, Sivkov VV, Molodtsov SL, Meissner H, Richter G, Hunoldt S, Kammer M, Paasch S, Krasokhin V, Patzke G, Brunner E, Richter W. Int. J. Biol. Macromol. 2010;47:141. doi: 10.1016/j.ijbiomac.2010.05.009. [DOI] [PubMed] [Google Scholar]
  • 6.Ehrlich H, Bazhenov VV, Debitus C, de Voogd N, Galli R, Tsurkan MV, Wysokowski M, Meissner H, Bulut E, Kaya M, Jesionowski T. Int. J. Biol. Macromol. 2017;104:1706. doi: 10.1016/j.ijbiomac.2017.01.141. [DOI] [PubMed] [Google Scholar]
  • 7.Brunner E, Ehrlich H, Schupp P, Hedrich R, Hunoldt S, Kammer M, Machill S, Paasch S, Bazhenov VV, Kurek DV, Arnold T, Brockmann S, Ruhnow M, Born R. J. Struct. Biol. 2009;168:539. doi: 10.1016/j.jsb.2009.06.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Cruz-Barraza JA, Carballo JL, Rocha-Olivares A, Ehrlich H, Hog M. PLoS One. 2012;7:e42049. doi: 10.1371/journal.pone.0042049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wysokowski M, Bazhenov VV, Tsurkan MV, Galli R, Stelling AL, Stöcker H, Kaiser S, Niederschlag E, Gärtner G, Behm T, Ilan M, Petrenko AY, Jesionowski T, Ehrlich H. Int. J. Biol. Macromol. 2013;62:94. doi: 10.1016/j.ijbiomac.2013.08.039. [DOI] [PubMed] [Google Scholar]
  • 10.Żółtowska-Aksamitowska S, Tsurkan MV, Lim SC, Meissner H, Tabachnick K, Shaala LA, Youssef DTA, Ivanenko VN, Petrenko I, Wysokowski M, Bechmann N, Joseph Y, Jesionowski T, Ehrlich H. Int. J. Biol. Macromol. 2018;112:1021. doi: 10.1016/j.ijbiomac.2018.02.071. [DOI] [PubMed] [Google Scholar]
  • 11.Shaala LA, Asfour HZ, Youssef DTA, Ółtowska-Aksamitowska SZ, Wysokowski M, Tsurkan M, Galli R, Meissner H, Petrenko I, Tabachnick K, Ivanenko VN, Bechmann N, Muzychka LV, Smolii OB, Martinović R, Joseph Y, Jesionowski T, Ehrlich H. Mar. Drugs. 2019;17:110566. doi: 10.3390/md17020092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fromont J, Żółtowska-Aksamitowska S, Galli R, Meissner H, Erpenbeck D, Vacelet J, Diaz C, Tsurkan MV, Petrenko I, Youssef DTA, Ehrlich H. Zool. Anz. 2019;280:21. doi: 10.1016/j.jcz.2019.03.002. [DOI] [Google Scholar]
  • 13.Schubert M, Binnewerg B, Voronkina A, Muzychka L, Wysokowski M, Petrenko I, Kovalchuk V, Tsurkan M, Martinovic R, Bechmann N, Ivanenko VN, Fursov A, Smolii OB, Fromont J, Joseph Y, Bornstein SR, Giovine M, Erpenbeck D, Guan K, Ehrlich H. Int. J. Mol. Sci. 2019;20:5105. doi: 10.3390/ijms20205105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Vacelet J, Erpenbeck D, Diaz C, Ehrlich H, Fromont J. Zool. Anz. 2019;280:14. doi: 10.1016/j.jcz.2019.03.001. [DOI] [Google Scholar]
  • 15.Klinger C, Żółtowska-Aksamitowska S, Wysokowski M, Tsurkan MV, Galli R, Petrenko I, Machałowski T, Ereskovsky A, Martinović R, Muzychka L, Smolii OB, Bechmann N, Ivanenko V, Schupp PJ, Jesionowski T, Giovine M, Joseph Y, Bornstein SR, Voronkina A, Ehrlich H, Klinger C, Żółtowska-Aksamitowska S, Wysokowski M, Tsurkan MV, Galli R, Petrenko I, Machałowski T, Ereskovsky A, Martinović R, Muzychka L, Smolii OB, Bechmann N, Ivanenko V, Schupp PJ, Jesionowski T, Giovine M, Joseph Y, Bornstein SR, Voronkina A, Ehrlich H. Mar. Drugs. 2019;17:131. doi: 10.3390/md17020131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tsurkan D, Wysokowski M, Petrenko I, Voronkina A, Khrunyk Y, Fursov A, Ehrlich H. Appl. Phys. A Mater. Sci. Process. 2020;126:1–9. doi: 10.1007/s00339-020-03564-9. [DOI] [Google Scholar]
  • 17.Petrenko I, Khrunyk Y, Voronkina A, Kovalchuk V, Fursov A, Tsurkan D. Lett. Appl. NanoBioScience. 2020;9:1004. doi: 10.33263/LIANBS92.10041014. [DOI] [Google Scholar]
  • 18.Thoms C, Ebel R, Proksch P. J. Chem. Ecol. 2006;32:97. doi: 10.1007/s10886-006-9355-x. [DOI] [PubMed] [Google Scholar]
  • 19.Moody K, Thomson RH, Fattorusso E, Minale L, Sodano G. J. Chem. Soc. Perkin Trans. 1972;1:18. doi: 10.1039/p19720000018. [DOI] [PubMed] [Google Scholar]
  • 20.Peng J, Li J, Hamann MT. Alkaloids. Chem. Biol. 2005;61:59. doi: 10.1016/s1099-4831(05)61002-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.R. C. Gandolfi, M. B. Medina, R. G. S. Berlinck, S. P. Lira, F. C. De Sá Galetti, C. L. Silva, K. Veloso, A. G. Ferreira, E. Hajdu, and S. Peixinho, Quim. Nova 33, 1853 (2010)
  • 22.Göthel Q, Sirirak T, Köck M. Beilstein J. Org. Chem. 2015;11:2334. doi: 10.3762/bjoc.11.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kalaitzis JA, de Leone PA, Hooper JNA, Quinn RJ. Nat. Prod. Res. 2008;22:1257. doi: 10.1080/14786410701763411. [DOI] [PubMed] [Google Scholar]
  • 24.Ragini K, Fromont J, Piggott AM, Karuso P. J. Nat. Prod. 2017;80:215. doi: 10.1021/acs.jnatprod.6b01038. [DOI] [PubMed] [Google Scholar]
  • 25.Kurimoto SI, Ohno T, Hokari R, Ishiyama A, Iwatsuki M, Ōmura S, Kobayashi J, Kubota T. Mar. Drugs. 2018;16:3. doi: 10.3390/md16120463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.El-Demerdash A, Moriou C, Toullec J, Besson M, Soulet S, Schmitt N, Petek S, Lecchini D, Debitus C, Al-Mourabit A. Mar. Drugs. 2018;16:146. doi: 10.3390/md16050146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Miguel-Gordo M, Gegunde S, Calabro K, Jennings LK, Alfonso A, Genta-Jouve G, Vacelet J, Botana LM, Thomas OP. Mar. Drugs. 2019;17:319. doi: 10.3390/md17060319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Salib MN, Jamison MT, Molinski TF. J. Nat. Prod. 2020;83:1532. doi: 10.1021/acs.jnatprod.9b01286. [DOI] [PubMed] [Google Scholar]
  • 29.R. Ebel, M. Brenzinger, A. Kunze, H. J. Gross, P. Proksch, Can. Field-Naturalist (1997)
  • 30.García-Vilas JA, Martínez-Poveda B, Quesada AR, Medina MÁ. Mar. Drugs. 2016;14:1. doi: 10.3390/md14010001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Teeyapant R, Kreis P, Proksch P, Woerdenbag HJ, Hacker J, Wray V, Witte L. Zeitschrift Fur Naturforsch. Sect. C J. Biosci. 1993;48:939. doi: 10.1515/znc-1993-11-1218. [DOI] [PubMed] [Google Scholar]
  • 32.Bayer M, Hellio C, Maréchal JP, Frank W, Lin W, Weber H, Proksch P. Mar. Biotechnol. 2011;13:1148. doi: 10.1007/s10126-011-9378-3. [DOI] [PubMed] [Google Scholar]
  • 33.Archila LGG, Zapata W, Galeano E, Martínez A, Díaz FJ, Rugeles MT. Vitae (Medellín) 2014;21:114. doi: 10.17533/udea.vitae.16797. [DOI] [Google Scholar]
  • 34.Niemann H, Marmann A, Lin W, Proksch P. Nat. Prod. Commun. 2015;10:219. [PubMed] [Google Scholar]
  • 35.Florean C, Schnekenburger M, Lee JY, Kim KR, Mazumder A, Song S, Kim JM, Grandjenette C, Kim JG, Yoon AY, Dicato M, Kim KW, Christov C, Han BW, Proksch P, Diederich M. Oncotarget. 2016;7:24027. doi: 10.18632/oncotarget.8210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Wang Q, Tang XL, Luo XC, de Voog NJ, Li PL, Li GQ. Sci. Rep. 2019;9:1. doi: 10.1038/s41598-018-37186-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kovalchuk V, Voronkina A, Binnewerg B, Schubert M, Muzychka L, Wysokowski M, Tsurkan MV, Bechmann N, Petrenko I, Fursov A, Martinovic R, Ivanenko VN, Fromont J, Smolii OB, Joseph Y, Giovine M, Erpenbeck D, Gelinsky M, Springer A, Guan K, Bornstein SR, Ehrlich H. Mar. Drugs. 2019;17:574. doi: 10.3390/md17100574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hikmawan BD, Wahyuono S, Setyowati EP. J. Appl. Pharm. Sci. 2020;10:142. [Google Scholar]
  • 39.Binnewerg B, Schubert M, Voronkina A, Muzychka L, Wysokowski M, Petrenko I, Djurović M, Kovalchuk V, Tsurkan M, Martinovic R, Bechmann N, Fursov A, Ivanenko VN, Tabachnick KR, Smolii OB, Joseph Y, Giovine M, Bornstein SR, Stelling AL, Tunger A, Schmitz M, Taniya OS, Kovalev IS, Zyryanov GV, Guan K, Ehrlich H. Mater. Sci. Eng. C. 2020;109:110566. doi: 10.1016/j.msec.2019.110566. [DOI] [PubMed] [Google Scholar]
  • 40.Shaala LA, Youssef DTA, Badr JM, Sulaiman M, Khedr A. Mar. Drugs. 2015;13:1621. doi: 10.3390/md13041621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Shaala LA, Youssef DTA, Badr JM, Sulaiman M, Khedr A, El Sayed KA. Tetrahedron. 2015;71:7837. doi: 10.1016/j.tet.2015.08.024. [DOI] [Google Scholar]
  • 42.Shaala LA, Youssef DTA. Biomolecules. 2019;9:841. doi: 10.3390/biom9120841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Bechmann N, Ehrlich H, Eisenhofer G, Ehrlich A, Meschke S, Ziegler C, Bornstein S, Bechmann N, Ehrlich H, Eisenhofer G, Ehrlich A, Meschke S, Ziegler CG, Bornstein SR. Mar. Drugs. 2018;16:172. doi: 10.3390/md16050172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Drechsel A, Helm J, Ehrlich H, Pantovic S, Bornstein SR, Bechmann N. Mar. Drugs. 2020;18:236. doi: 10.3390/md18050236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Olatunji OJ, Ogundajo AL, Oladosu IA, Changwichit K, Ingkaninan K, Yuenyongsawad S, Plubrukarn A. Nat. Prod. Commun. 2014;9:1559. [PubMed] [Google Scholar]
  • 46.Rohde S, Schupp PJ. Hydrobiologia. 2012;687:219. doi: 10.1007/s10750-011-0774-5. [DOI] [Google Scholar]
  • 47.Ereskovsky AV, Tokina DB, Saidov DM, Baghdiguian S, Le Goff E, Lavrov AI. J. Exp. Zool. Part B Mol. Dev. Evol. 2020;334:37. doi: 10.1002/jez.b.22919. [DOI] [PubMed] [Google Scholar]
  • 48.Pronzato R, Bavestrello G, Cerrano C, Magnino G, Manconi R, Pantelis J, Sarà A, Sidri M. Mem. Queensl. Museum. 1999;44:485. [Google Scholar]
  • 49.Hausmann R, Vitello MP, Leitermann F, Syldatk C. J. Biotechnol. 2006;124:117. doi: 10.1016/j.jbiotec.2006.03.033. [DOI] [PubMed] [Google Scholar]
  • 50.Klöppel A, Pfannkunchen M, Putz A, Proksch P, Brümmer F. Mar. Ecol. 2008;29:259. doi: 10.1111/j.1439-0485.2008.00225.x. [DOI] [Google Scholar]
  • 51.Ehrlich H, Bazhenov V, Meschke S, Bürger M, Ehrlich A, Petovic S, Durovic M. Handb. Environ. Chem. Berlin: Springer; 2017. pp. 313–334. [Google Scholar]
  • 52.Sharma GM, Burkholder PR. J. Antibiot. (Tokyo). 1967;20:200. [PubMed] [Google Scholar]
  • 53.Sharma GM, Burkholder PR. Tetrahedron Lett. 1967;8:4147. doi: 10.1016/S0040-4039(01)89710-0. [DOI] [PubMed] [Google Scholar]
  • 54.Shaкma GM, Vig B, Burkholder PR. J. Org. Chem. 1970;35:2823. doi: 10.1021/jo00833a084. [DOI] [PubMed] [Google Scholar]
  • 55.Nuñez CV, de Almeida EVR, Granato AC, Marques SO, Santos KO, Pereira FR, Macedo ML, Ferreira AG, Hajdu E, Pinheiro US, Muricy G, Peixinho S, Freeman CJ, Gleason DF, Berlinck RGS. Biochem. Syst. Ecol. 2008;36:283. doi: 10.1016/j.bse.2007.09.008. [DOI] [Google Scholar]
  • 56.Calcul L, Inman WD, Morris AA, Tenney K, Ratnam J, McKerrow JH, Valeriote FA, Crews P. J. Nat. Prod. 2010;73:365. doi: 10.1021/np9005986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Silva MM, Bergamasco J, Lira SP, Lopes NP, Hajdu E, Peixinho S, Berlinck RGS. Aust. J. Chem. 2010;63:886. doi: 10.1071/CH09616. [DOI] [Google Scholar]
  • 58.Kalaitzis JA, Davis RA, Quinn RJ. Magn. Reson. Chem. 2012;50:749. doi: 10.1002/mrc.3868. [DOI] [PubMed] [Google Scholar]
  • 59.Ebada SS, Proksch P. Handb. Mar. Nat. Prod. Netherlands: Springer; 2012. pp. 191–293. [Google Scholar]
  • 60.Niemann H, Lin W, Müller WEG, Kubbutat M, Lai D, Proksch P. J. Nat. Prod. 2013;76:121. doi: 10.1021/np300764u. [DOI] [PubMed] [Google Scholar]
  • 61.Mathieu V, Wauthoz N, Lefranc F, Niemann H, Amighi K, Kiss R, Proksch P. Molecules. 2013;18:3543. doi: 10.3390/molecules18033543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Putz A, Proksch P. Annu. Plant Rev. Online. Chichester: Wiley; 2018. pp. 162–213. [Google Scholar]
  • 63.Kurimoto SI, Seino S, Fromont J, Kobayashi J, Kubota T. Org. Lett. 2019;21:8824. doi: 10.1021/acs.orglett.9b03457. [DOI] [PubMed] [Google Scholar]
  • 64.Tintillier F, Moriou C, Petek S, Fauchon M, Hellio C, Saulnier D, Ekins M, Hooper JNA, Al-Mourabit A, Debitus C. Mar. Drugs. 2020;18:272. doi: 10.3390/md18050272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Wasserman HH, Wang J. J. Org. Chem. 1998;63:5581. doi: 10.1021/jo980860m. [DOI] [Google Scholar]
  • 66.Moreels L, Bhat C, Voráčová M, Peigneur S, Goovaerts H, Mäki-Lohiluoma E, Zahed F, Pardo LA, Yli-Kauhaluoma J, Kiuru P, Tytgat J. PLoS One. 2017;12:e0188811. doi: 10.1371/journal.pone.0188811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Bhat C, Ilina P, Tilli I, Voráčová M, Bruun T, Barba V, Hribernik N, Lillsunde K-E, Mäki-Lohiluoma E, Rüffer T, Lang H, Yli-Kauhaluoma J, Kiuru P, Tammela P. Mar. Drugs. 2018;16:481. doi: 10.3390/md16120481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Thompson JE, Barrow KD, Faulkner DJ. Acta Zool. 1983;64:199. doi: 10.1111/j.1463-6395.1983.tb00801.x. [DOI] [Google Scholar]
  • 69.Thompson JE. Mar. Biol. 1985;88:23. doi: 10.1007/BF00393039. [DOI] [Google Scholar]
  • 70.Walker RP, Thompson JE, Faulkner DJ. Mar. Biol. 1985;88:27. doi: 10.1007/BF00393040. [DOI] [Google Scholar]
  • 71.Vacelet J. J. Microsc. 1967;6:237. [Google Scholar]
  • 72.Kunze K, Niemann H, Ueberlein S, Schulze R, Ehrlich H, Brunner E, Proksch P, Van Pée KH. Mar. Drugs. 2013;11:1271. doi: 10.3390/md11041271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Ueberlein S, Machill S, Niemann H, Proksch P, Brunner E. Mar. Drugs. 2014;12:4417. doi: 10.3390/md12084417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.K. Sepčić, U. Batista, J. Vacelet, P. MačEk, and T. Turk, Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. 117, 47 (1997) [DOI] [PubMed]
  • 75.Abou-Shoer MI, Shaala LA, Youssef DTA, Badr JM, Habib A-AM. J. Nat. Prod. 2008;71:1464. doi: 10.1021/np800142n. [DOI] [PubMed] [Google Scholar]
  • 76.L. Minale, G. Sodano, W. R. Chan, and A. M. Chen, J. Chem. Soc. Chem. Commun. 0, 674 (1972)
  • 77.Shestak OP, Novikov VL, Ivanova EP, Gorshkova NM. Pharm. Chem. J. 2001;35:366. doi: 10.1023/A:1012799002863. [DOI] [Google Scholar]
  • 78.Balouiri M, Sadiki M, Ibnsouda SK. J. Pharm. Anal. 2016;6:71. doi: 10.1016/j.jpha.2015.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Magaldi S, Mata-Essayag S, Hartung de Capriles C, Perez C, Colella M, Olaizola C, Ontiveros Y, Ellis M, Ain A. Int. J. Infect. Dis. 2004;8:39. doi: 10.1016/j.ijid.2003.03.002. [DOI] [PubMed] [Google Scholar]
  • 80.Valgas C, De Souza SM, Smânia EFA, Smânia A. Braz. J. Microbiol. 2007;38:369. doi: 10.1590/S1517-83822007000200034. [DOI] [Google Scholar]
  • 81.CLSI, Approved Standard, 9th ed., CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne (2012)
  • 82.N. S. Lira, R. C. Montes, J. F. Tavares, M. S. Da Silva, E. V. L. Da Cunha, P. F. De Athayde-Filho, L. C. Rodrigues, C. Da Silva Dias, J. M. Barbosa-Filho, Mar. Drugs 9, 2316 (2011) [DOI] [PMC free article] [PubMed]
  • 83.Ciminiello P, Dell’Aversano C, Fattorusso E, Magno S, Carrano L, Pansini M. Tetrahedron. 1996;52:9863. doi: 10.1016/0040-4020(96)00518-2. [DOI] [Google Scholar]
  • 84.Ciminiello P, Fattorasso E, Forino M, Magno S, Pansini M. Tetrahedron. 1997;53:6565. doi: 10.1016/S0040-4020(97)00311-6. [DOI] [Google Scholar]
  • 85.Fattorusso E, Minale L, Sodano G. J. Chem. Soc. Perkin Trans. 1972;1(1):16. doi: 10.1039/p19720000016. [DOI] [PubMed] [Google Scholar]
  • 86.Cruz F, Quijano L, Gómez-Garibay F, Rios T. J. Nat. Prod. 1990;53:543. doi: 10.1021/np50069a001. [DOI] [Google Scholar]
  • 87.Ciminiello P, Constantino V, Fattorusso E, Magno S, Mangoni A, Pansini M. J. Nat. Prod. 1994;57:705–712. doi: 10.1021/np50108a004. [DOI] [Google Scholar]
  • 88.Shaker KH, Zinecker H, Ghani MA, Imhoff JF, Schneider B. Chem. Biodivers. 2010;7:2880. doi: 10.1002/cbdv.200900277. [DOI] [PubMed] [Google Scholar]
  • 89.Cimino G, De Rosa S, De Stefano S, Self R, Sodano G. Tetrahedron Lett. 1983;24:3029. doi: 10.1016/S0040-4039(00)88087-9. [DOI] [Google Scholar]
  • 90.Wilkinson CR, Vacelet J. J. Exp. Mar. Bio. Ecol. 1979;37:91. doi: 10.1016/0022-0981(79)90028-5. [DOI] [Google Scholar]
  • 91.Thoms C, Wolff M, Padmakumar K, Ebel R, Proksch P. Zeitschrift Fur Naturforsch. Sect. C J. Biosci. 2004;59:113. doi: 10.1515/znc-2004-1-222. [DOI] [PubMed] [Google Scholar]
  • 92.J. Shearman, Bromotyrosine-Derived Natural Products: Synthetic and Biological Studies (Doctoral Thesis), Univ. of Cambridge (2011)
  • 93.Blaskovich MAT, Elliott AG, Kavanagh AM, Ramu S, Cooper MA. Sci. Rep. 2019;9:1. doi: 10.1038/s41598-019-50746-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Kamei Y, Sueyoshi M, Hayashi KI, Terada R, Nozaki H. J. Antibiot. 2009;62:259. doi: 10.1038/ja.2009.25. [DOI] [PubMed] [Google Scholar]
  • 95.Martin T, Jahn T, et al. Cell Host Microbe. 2019;26:542–550. doi: 10.1016/j.chom.2019.08.019. [DOI] [PubMed] [Google Scholar]
  • 96.Welsh JE, Steenhuis P, de Moraes KR, van der Meer J, Thieltges DW, Brussaard CPD. Sci. Rep. 2020;10:5221. doi: 10.1038/s41598-020-61691-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Gomez-Archila LG, et al. Vitae. 2014;21:114–125. doi: 10.17533/udea.vitae.16797. [DOI] [Google Scholar]
  • 98.Tsurkan M, Voronkina A, Khrunyk Y, Wysokowski M, Petrenko I, Ehrlich H. Carb. Polym. 2021;252:117204. doi: 10.1016/j.carbpol.2020.117204. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Applied Physics. A, Materials Science & Processing are provided here courtesy of Nature Publishing Group

RESOURCES